PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19381165-2	2009	We assessed whether a genetic variation in the SLC22A1 gene is associated with the glucose-lowering effect of metformin.	Glucose	83-90	solute carrier family 22 member 1	Homo sapiens	47-54	
25492374-3	2015	It has been hypothesized that genetic variations of SLC22A1 gene will influence inter-individual variation in glucose lowering efficacy of metformin.	Glucose	110-117	solute carrier family 22 member 1	Homo sapiens	52-59	
24740684-10	2015	This observational study showed that the variant OCT1-Met420del may be more effective on plasma glucose than HbA1c.	Glucose	96-103	solute carrier family 22 member 1	Homo sapiens	49-53	
25060604-1	2014	AIM: The organic cation transporter 1 (OCT1) plays a key role in the cellular transport of metformin and its subsequent glucose-lowering effect.	Glucose	120-127	solute carrier family 22 member 1	Homo sapiens	9-37	
25060604-1	2014	AIM: The organic cation transporter 1 (OCT1) plays a key role in the cellular transport of metformin and its subsequent glucose-lowering effect.	Glucose	120-127	solute carrier family 22 member 1	Homo sapiens	39-43	
19898263-2	2010	Recently, we discovered that polymorphisms rs622342 A>C in the SLC22A1 gene, coding for OCT1, and rs2289669 G>A in the SLC47A1 gene, coding for MATE1, are associated with the degree of glucose lowering by metformin.	Glucose	191-198	solute carrier family 22 member 1	Homo sapiens	66-73	
19898263-2	2010	Recently, we discovered that polymorphisms rs622342 A>C in the SLC22A1 gene, coding for OCT1, and rs2289669 G>A in the SLC47A1 gene, coding for MATE1, are associated with the degree of glucose lowering by metformin.	Glucose	191-198	solute carrier family 22 member 1	Homo sapiens	91-95	
19898263-9	2010	CONCLUSION: The effect of the MATE1 rs2289669 polymorphism on the glucose lowering effect of metformin is larger in incident users with the OCT1 rs622342 CC genotype than in incident users with the AA genotype.	Glucose	66-73	solute carrier family 22 member 1	Homo sapiens	140-144	
21270793-6	2011	Our results suggest that rifampin increases OCT1 expression and hepatic uptake of metformin, leading to enhanced glucose-lowering action.	Glucose	113-120	solute carrier family 22 member 1	Homo sapiens	44-48	
21241070-14	2011	An intron variant of OCT1 (single nucleotide polymorphism [SNP] rs622342) has been associated with a decreased effect on blood glucose in heterozygotes and a lack of effect of metformin on plasma glucose in homozygotes.	Glucose	127-134	solute carrier family 22 member 1	Homo sapiens	21-25	
21241070-14	2011	An intron variant of OCT1 (single nucleotide polymorphism [SNP] rs622342) has been associated with a decreased effect on blood glucose in heterozygotes and a lack of effect of metformin on plasma glucose in homozygotes.	Glucose	196-203	solute carrier family 22 member 1	Homo sapiens	21-25	
19381165-9	2009	To conclude, genetic variation at rs622342 in the SLC22A1 gene was associated with the glucose-lowering effect of metformin in patients with diabetes mellitus.	Glucose	87-94	solute carrier family 22 member 1	Homo sapiens	50-57	
19336679-2	2009	In 12 normoglycemic individuals, reduced-function variants in SLC22A1 were shown to decrease the ability of metformin to reduce glucose excursion in response to oral glucose.	Glucose	128-135	solute carrier family 22 member 1	Homo sapiens	62-69	
19336679-2	2009	In 12 normoglycemic individuals, reduced-function variants in SLC22A1 were shown to decrease the ability of metformin to reduce glucose excursion in response to oral glucose.	Glucose	166-173	solute carrier family 22 member 1	Homo sapiens	62-69